<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药物探索 | wechat-feeds</title><link>http://MzU3NzU1OTg1OQ.favicon.privacyhide.com/favicon.ico</link><description>医药相关领域的信息分享和分析</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 26 Jan 2021 20:48:47 +0800</pubDate><image><url>http://MzU3NzU1OTg1OQ.favicon.privacyhide.com/favicon.ico</url><title>药物探索 | wechat-feeds</title><link>http://MzU3NzU1OTg1OQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>首个EGFR/MUC1特异性抗体ADC药物M1231，临床开始</title><link>https://mp.weixin.qq.com/s/4gRCuRCw7MtTWMQDJ5MJgw</link><description></description><content:encoded><![CDATA[首个EGFR/MUC1特异性抗体ADC药物M1231，临床开始]]></content:encoded><pubDate>Tue, 26 Jan 2021 18:30:30 +0800</pubDate></item><item><title>2021々广东新契未来管线洞察KRAS G12C/HPK1</title><link>https://mp.weixin.qq.com/s/8dJNGUGnriEScl5St--G7Q</link><description></description><content:encoded><![CDATA[2021々广东新契未来管线洞察KRAS G12C/HPK1]]></content:encoded><pubDate>Mon, 25 Jan 2021 22:06:11 +0800</pubDate></item><item><title>Nature子刊｜抗体衍生化合物（Abd）技术，筛选泛RAS抑制剂</title><link>https://mp.weixin.qq.com/s/ysjg1DxWBDtAbIvts3A0mw</link><description></description><content:encoded><![CDATA[Nature子刊｜抗体衍生化合物（Abd）技术，筛选泛RAS抑制剂]]></content:encoded><pubDate>Tue, 19 Jan 2021 16:17:18 +0800</pubDate></item><item><title>管线梳理｜KRAS G12C</title><link>https://mp.weixin.qq.com/s/myOiSQJws6mxgGoO2ev-6A</link><description></description><content:encoded><![CDATA[管线梳理｜KRAS G12C]]></content:encoded><pubDate>Sun, 17 Jan 2021 13:06:48 +0800</pubDate></item><item><title>短讯｜诺华ligelizumab (QGE031)获首个慢性自发性荨麻疹BTD</title><link>https://mp.weixin.qq.com/s/lAT-UyMpdzaRe3XjVOF0uA</link><description></description><content:encoded><![CDATA[短讯｜诺华ligelizumab (QGE031)获首个慢性自发性荨麻疹BTD]]></content:encoded><pubDate>Sun, 17 Jan 2021 11:54:48 +0800</pubDate></item><item><title>国内再来一款KRAS G12C，Enhertu新适应症获批。。。</title><link>https://mp.weixin.qq.com/s/3ulf-78FKoEJIjS4_2MnxA</link><description></description><content:encoded><![CDATA[国内再来一款KRAS G12C，Enhertu新适应症获批。。。]]></content:encoded><pubDate>Sat, 16 Jan 2021 22:33:06 +0800</pubDate></item><item><title>国内第3款MET/EGFR特异性双抗，MET/EGFR ADC会有吗？</title><link>https://mp.weixin.qq.com/s/rfXi_7amS22hVFJfJBv_gg</link><description></description><content:encoded><![CDATA[国内第3款MET/EGFR特异性双抗，MET/EGFR ADC会有吗？]]></content:encoded><pubDate>Sun, 10 Jan 2021 11:22:52 +0800</pubDate></item><item><title>Fast Follow是什么，更多的仍是Me-too</title><link>https://mp.weixin.qq.com/s/8AhCh-521dP6Vf9z6qR5OA</link><description></description><content:encoded><![CDATA[Fast Follow是什么，更多的仍是Me-too]]></content:encoded><pubDate>Sat, 09 Jan 2021 10:07:35 +0800</pubDate></item><item><title>SHP2分子开发，下一步走向何方？</title><link>https://mp.weixin.qq.com/s/FT41YY8jjXnbIrQ0IeG4ig</link><description></description><content:encoded><![CDATA[SHP2分子开发，下一步走向何方？]]></content:encoded><pubDate>Sun, 03 Jan 2021 11:05:52 +0800</pubDate></item><item><title>加科思SHP2数据公布，好还是不好呢？</title><link>https://mp.weixin.qq.com/s/JOTL4Q69koHDssCq8pG4vg</link><description></description><content:encoded><![CDATA[加科思SHP2数据公布，好还是不好呢？]]></content:encoded><pubDate>Sat, 19 Dec 2020 09:01:57 +0800</pubDate></item></channel></rss>